The landscape of maternal healthcare and diabetes management reached a significant milestone on October 28, when Glooko, Inc., a prominent global digital health company, unveiled real-world data at the Diabetes Technology Society (DTS) meeting. The presentation focused on the efficacy and safety of EndoTool IV, a sophisticated computerized intravenous insulin dosing application, specifically within the high-stakes environment of labor and delivery (L&D). As clinical teams grapple with the complexities of maintaining glycemic stability during childbirth, the data presented offers a compelling case for the integration of automated decision-support tools in inpatient settings.
The retrospective analysis, titled “Use of a Computerized Intravenous Insulin Dosing Application in Pregnancy,” scrutinized outcomes from 267 individuals across 43 diverse healthcare facilities. The data, drawn from the 2025 EndoTool IV database, provides a comprehensive look at how digital intervention can mitigate the risks of both hyperglycemia and hypoglycemia during one of the most physiologically dynamic periods in a patient’s life. By comparing outcomes across Type 1 diabetes, Type 2 diabetes, and Gestational Diabetes Mellitus (GDM), the study highlights the versatility of personalized insulin dosing.
The Clinical Challenge of Glycemic Management in Labor and Delivery
Managing blood glucose levels during labor and delivery is widely recognized by endocrinologists and obstetricians as a "metabolic tightrope." During the active phase of labor, the physical exertion of the mother, coupled with the stress response of the body, can cause significant fluctuations in insulin sensitivity. Conversely, the moment the placenta is delivered, there is a precipitous drop in insulin resistance, often leading to a sudden and dangerous increase in insulin sensitivity.
Traditional methods of managing these shifts often relied on manual "sliding scale" protocols or paper-based intravenous insulin charts. These methods, while standard for decades, are frequently criticized for being reactive rather than proactive, often leading to a "yo-yo" effect where patients bounce between high and low glucose levels. For the mother, hyperglycemia during labor increases the risk of metabolic acidosis and dehydration. For the neonate, maternal hyperglycemia can trigger fetal hyperinsulinemia, which may result in severe neonatal hypoglycemia immediately after birth, as well as an increased risk of respiratory distress syndrome.
The introduction of EndoTool IV into this environment seeks to replace manual calculations with a predictive algorithm. By utilizing patient-specific data—including weight, current glucose levels, and the rate of change—the system provides clinicians with precise dosing recommendations designed to reach a specific target range safely and maintain it through the duration of the delivery process.
Detailed Findings from the DTS Presentation
The real-world data presented at the DTS meeting underscored the reliability of computerized dosing in a varied patient population. The study’s cohort of 267 individuals represented a cross-section of the modern obstetric population, including those with pre-existing conditions and those who developed diabetes during pregnancy.
A primary highlight of the findings was the achievement of tight glycemic control without a single observed instance of severe hypoglycemia across the evaluated patients. In clinical terms, severe hypoglycemia is typically defined as a blood glucose level low enough to require third-party assistance or to cause neurological impairment. Eliminating this risk in a laboring patient is a significant safety achievement, as hypoglycemia can complicate the delivery process and necessitate emergency interventions.
Furthermore, the data indicated that the EndoTool IV system was equally effective across different types of diabetes. While Type 1 patients often present the highest level of complexity due to a total lack of endogenous insulin, the system successfully navigated their needs alongside the requirements of patients with GDM and Type 2 diabetes. This suggests that the algorithm’s personalized approach is robust enough to handle the varying degrees of insulin resistance and secretion found in these distinct patient groups.
Chronology of Innovation: Glooko’s Path to Integrated Care
The presentation of this data is part of a broader chronological progression for Glooko as it transitions from a specialized diabetes data platform to a comprehensive glycemic management ecosystem.
Originally known for its ambulatory (outpatient) solutions that allowed patients to sync data from insulin pumps and continuous glucose monitors (CGMs) to a mobile app for physician review, Glooko has aggressively expanded its footprint into the inpatient sector. A pivotal moment in this timeline was the acquisition of technologies like EndoTool, which allowed the company to address the "missing link" in diabetes care: the period when a patient is hospitalized.
In recent months, Glooko has further refined its pregnancy-specific offerings. The launch of GestationalCare™, a module specifically designed for the ambulatory management of pregnancy-related diabetes, preceded the current L&D data release. This module was created to help care teams monitor fasting and post-meal glucose patterns during the second and third trimesters. By following this with the EndoTool IV data for labor and delivery, Glooko has effectively mapped out a technological roadmap for the entire pregnancy journey—from the first diagnosis of GDM through the postpartum transition.
Expert Perspectives and Clinical Implications
The data has garnered positive reactions from the medical community, particularly from those specializing in the intersection of endocrinology and maternal-fetal medicine. Joseph Aloi, MD, an Endocrine Society member and section chief of Endocrinology and Metabolism at Advocate Health, Wake Forest University School of Medicine, served as a key voice in interpreting these findings.
"Labor and delivery represents a uniquely dynamic period for glycemic management, when insulin requirements can change quickly and clinicians need to maintain tight glucose targets while minimizing the risk of hypoglycemia," Dr. Aloi stated. He emphasized that the "real-world" nature of the findings—meaning the data came from actual clinical practice across dozens of hospitals rather than a strictly controlled clinical trial—adds a layer of practical validity to the results. "These real-world findings are encouraging because they show that personalized intravenous insulin dosing with EndoTool can support tight glycemic control in this population, with no observed instances of severe hypoglycemia across the patients evaluated."
Mark Clements, MD, PhD, Glooko’s Chief Medical and Strategy Officer, echoed these sentiments, focusing on the continuity of care. He noted that diabetes management in pregnancy is often fragmented, with patients moving between primary care, specialized obstetricians, and hospital nursing staff. "A person may need close outpatient monitoring throughout pregnancy, precise insulin management during labor and delivery, and continued support as her care transitions postpartum," Clements explained. He argued that the DTS data reinforces the vision of a "connected" platform where data and dosing logic are consistent regardless of the clinical setting.
Broader Impact on Healthcare Systems and Patient Outcomes
The implications of the EndoTool IV data extend beyond immediate clinical safety to broader healthcare economics and hospital efficiency. In an era of nursing shortages and high clinician burnout, the automation of complex insulin calculations can significantly reduce the cognitive load on L&D nursing staff. Manual IV insulin protocols require frequent monitoring and complex math; a computerized system that provides the "next step" recommendation can streamline workflows and reduce the potential for human error.
From a patient outcome perspective, the consistent maintenance of euglycemia (normal blood sugar) during labor has long-term benefits. Reducing the incidence of neonatal hypoglycemia means fewer admissions to the Neonatal Intensive Care Unit (NICU), which is one of the most significant cost drivers in obstetric care. By stabilizing the mother’s glucose, the hospital can potentially improve the health of the newborn, facilitating immediate skin-to-skin contact and successful breastfeeding initiation, both of which are hindered when a baby must be rushed to the NICU for glucose stabilization.
Furthermore, the integration of tools like GestationalCare™ and EndoTool IV addresses the growing global burden of hyperglycemia in pregnancy. According to the International Diabetes Federation, approximately one in six live births is affected by some form of hyperglycemia in pregnancy. As maternal age increases and obesity rates rise, the prevalence of GDM and Type 2 diabetes in the obstetric population is expected to climb. Scalable, digital solutions are increasingly seen as the only way to manage this volume of patients effectively.
Analysis: The Future of Digital Glycemic Management
The findings presented at the DTS meeting suggest a shift in the standard of care for inpatient diabetes management. As healthcare moves toward "Value-Based Care," tools that can demonstrate a reduction in adverse events (like severe hypoglycemia) while improving efficiency will become indispensable.
Glooko’s strategy of connecting ambulatory data with inpatient tools represents a move toward "Precision Medicine" in diabetes. By using algorithms that learn from patient data in real-time, the medical community is moving away from the "one-size-fits-all" approach that has dominated hospital protocols for decades. The success of EndoTool IV in the labor and delivery ward provides a blueprint for how similar technologies might be applied in other high-intensity hospital settings, such as surgical suites or intensive care units.
In conclusion, the data presented on October 28 serves as a validation of computerized insulin dosing in one of medicine’s most sensitive environments. By proving that tight control is possible without compromising safety, Glooko has positioned its technology as a critical component of modern maternal care. As the company continues to expand its platform, the focus remains on reducing the fragmentation of care and providing a seamless, data-driven experience for both patients and the clinicians who support them through the complexities of pregnancy and birth.
